EGFR and non-small cell lung carcinoma: Preclinical and clinical data (AURA3) [34, 65] support the ability of Osi to cross the blood-brain barrier and penetrate the CNS; the PFS of advanced EGFR-mutant NSCLC in the FLAURA trial [42] was significantly enhanced in the Osi group.